Cipla gets EIR from USFDA for Kurkumbh facility
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
Pharma major Cipla Monday said it has received establishment inspection report (EIR) from the US health regulator after inspection of Kurkumbh facility in Maharashtra.
The Kurkumbh manufacturing facility was inspected by the United States Food and Drug Administration (USFDA) from March 11 to March 20, 2019, Cipla said in a BSE filing.
The company has received the EIR indicating closure of the inspection, it added.
Shares of Cipla closed at Rs 553.70 per scrip on the BSE, up 0.75 per cent from its previous close.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SIP in Stocks For New Year 2025: Market guru Anil Singhvi recommends 1 largecap, 2 midcap scrips to buy in dips; note down targets
Top 7 Index Mutual Funds With Best SIP Returns in 10 Years: Rs 11,111 monthly SIP investment in No. 1 fund is now worth Rs 33,18,831; know how others have fared
SIP Stock Pick For New Year 2025: Anil Singhvi recommends buying this largecap pharma stock on 10% dip
Shark Tank India Season 4: Social Media influencer Gaurav Taneja shocks sharks with his earnings, earns Rs 1 crore in 1 hour!
Largecap PSU Stock for 65% Gain in New Year: Anil Singhvi picks PSU bank for long term; know reasons and target prices
Largecap Stocks To Buy: Analysts recommend buying Maruti Suzuki, 2 other stocks for 2 weeks; check targets
SBI Latest FD Rates: PSU bank pays these returns to senior citizens and other depositors on 1-year, 3-year and 5-year fixed deposits
06:38 PM IST